landiolol has been researched along with Atrial Fibrillation in 81 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (14.81) | 29.6817 |
| 2010's | 51 (62.96) | 24.3611 |
| 2020's | 18 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, T; Ebina, T; Hanajima, Y; Hibi, K; Horii, M; Iwahashi, N; Kimura, K; Kimura, Y; Kirigaya, J; Kosuge, M; Matsuzawa, Y; Minamimoto, Y; Okada, K; Takahashi, H; Tamura, K | 1 |
| Fejér, C; Gellér, L; Kiss, B; Kovács, E; Merkely, B; Pilecky, D; Radics, P; Ruzsa, Z; Straub, É; Zima, E | 1 |
| Cazenave, L; Fellahi, JL; Ferraris, A; Fornier, W; Jacquet-Lagrèze, M; Jalalzai, W; Pozzi, M; Rousseau-Saine, N | 1 |
| Aoki, H; Fukunaga, H; Horigome, H; Miura, M; Miyazaki, A; Morishima, E; Ohashi, N; Oki, K; Ono, H; Sagawa, K; Sakaguchi, H; Sato, S; Sumitomo, N; Suzuki, T; Takei, K; Ueda, H | 1 |
| Abe, T; Hagiwara, N; Jujo, K; Kametani, M; Minami, Y; Shiga, T; Shirotani, S; Suzuki, A | 1 |
| Katsube, T; Kawakami, A; Kobayashi, Y | 1 |
| Besnier, E; Briant, AR; Caspersen, E; Denisenko, A; Descamps, R; Fellahi, JL; Fischer, MO; Gaudard, P; Guinot, PG; Hanouz, JL; Lorne, E; Mahjoub, Y; Mongardon, N; Moussa, MD; Oilleau, JF; Parienti, JJ; Paul, LPS; Rozec, B; Tomadesso, C | 1 |
| Allwood, M; Belley-Côté, EP; Borges, FK; Cafaro, T; Conen, D; Daza, J; Devereaux, PJ; Healey, JS; Ke Wang, M; Lamy, A; Marcucci, M; McGillion, M; McIntyre, WF; Ofori, SN; Park, LJ; Spence, JD; Whitlock, RP | 1 |
| Er, F; Gassanov, N | 1 |
| Domanovits, H; Hodisch, J; Husch, B; Kadlecová, P; Krumpl, G; Stix, G; Trebs, M; Unger, M; Wolzt, M | 1 |
| Heringlake, M; Walter, E | 1 |
| Muehlschlegel, JD; O'Brien, B | 1 |
| Akiyama, M; Ito, K; Kaiho, Y; Katahira, S; Kumagai, K; Maeda, K; Matsuo, S; Saiki, Y; Sasaki, K; Sugawara, Y; Suzuki, T; Suzuki, Y; Tsuji, I | 1 |
| Imamura, T; Kinugawa, K | 1 |
| Akitsu, K; Fujino, T; Ikeda, T; Kinoshita, T; Koike, H; Shinohara, M; Suzuki, T; Wada, R; Yano, K | 1 |
| Ait-Oufella, H; Baudel, JL; Bige, N; Hariri, G; Mazerand, S; Urbina, T | 1 |
| Enomoto, D; Hyodo, T; Ikeda, S; Okura, T; Sakaue, T; Takahashi, K; Takemoto, M; Uemura, S; Utsunomiya, Y; Yamashita, M | 1 |
| Allaouchiche, B; Cazenave, L; Fellahi, JL; Ferraris, A; Fornier, W; Jacquet-Lagrèze, M; Jalalzai, W; Junot, S; Pozzi, M; Rousseau-Saine, N | 1 |
| Ashida, A; Kishi, K; Konishi, H; Nemoto, S; Odanaka, Y; Ozaki, N | 1 |
| Chen, C; Hao, J; Liu, L; Peng, H; Xu, W; Zhang, J; Zhou, J | 1 |
| Goyagi, T; Horiguchi, T; Horikoshi, Y; Kodama, S; Kudo, R; Nishikawa, T | 1 |
| Hayata, K; Kato, T; Katsuda, M; Kitadani, J; Nakamori, M; Nakamura, M; Ojima, T; Tabata, H; Takeuchi, A; Yamaue, H | 1 |
| Fujita, M; Godo, S; Kawazoe, Y; Kudo, D; Kushimoto, S; Nomura, R; Ozaki, H; Shimokawa, H | 1 |
| Tamura, T; Yatabe, T; Yokoyama, M | 1 |
| Syed, YY | 1 |
| Kugo, Y; Nishi, H; Sekiya, N; Takahashi, T; Yamada, M | 1 |
| Akhtar, K; Asaad, P; Hajibandeh, S; Melhado, R; Trivedi, V | 1 |
| Fujimoto, Y; Hayashi, H; Hayashi, M; Ito-Hagiwara, K; Iwasaki, YK; Maru, E; Oka, E; Shimizu, W; Yamamoto, T; Yodogawa, K | 1 |
| Imamura, T; Nitta, D | 1 |
| Iwasaki, YK; Oka, E; Shimizu, W | 1 |
| Mizutani, H; Nakasu, Y; Sumitani, K; Yamashita, T | 1 |
| Arai, H; Makita, S; Miyagi, N; Nagaoka, E; Tamura, K | 1 |
| Hayata, K; Iida, T; Iwahashi, M; Katsuda, M; Nakamori, M; Nakamura, M; Ojima, T; Yamaue, H | 1 |
| Adachi, T; Aonuma, K; Baba, M; Hasegawa, T; Hiraya, D; Hoshi, T; Kuroki, K; Sato, A | 1 |
| Doi, M; Kobayashi, S; Matsuzaki, M; Murakami, W; Myoren, T; Nao, T; Okuda, S; Tateishi, H; Wada, Y; Yano, M | 1 |
| Ishitoya, H; Maisawa, K; Shimamura, Y; Yamazaki, K | 1 |
| Aoki, M; Baba, H; Goto, Y; Ogawa, S; Okawa, Y | 1 |
| Aiba, T; Atarashi, H; Daimon, T; Fujino, K; Hori, M; Ikeda, T; Imai, Y; Inoue, H; Kinugawa, K; Kitakaze, M; Nagai, R; Nagano, T; Okamura, T; Sakamoto, A; Seino, Y; Shimizu, W; Yamashita, T | 1 |
| Bian, C; Jian, Y; Liu, S; Liu, W; Zhang, Y | 1 |
| Hamasaki, T; Kitakaze, M; Sakamoto, A | 1 |
| Sezai, A; Shiono, M | 1 |
| Kamiya, S; Minematsu, N; Morita, Y; Nishimi, M; Osumi, M; Tashiro, T; Wada, H | 1 |
| Fujii, T; Fujiwara, M; Iwata, N; Kobayashi, D; Kodera, Y; Koike, M; Nakayama, G; Niwa, Y; Sugimoto, H; Tanaka, C | 1 |
| Matsushita, M; Saitoh, T; Yamashita, T | 1 |
| Abe, M; Akao, M; Hamatani, Y; Iguchi, M; Ishii, M; Masunaga, N; Nakatani, R; Ogawa, H; Takagi, D; Unoki, T; Usui, T; Yamashita, Y | 1 |
| Arimoto, M; Hata, H; Ishii, Y; Osaka, S; Sezai, A; Shiono, M; Yaoita, H | 1 |
| Amiya, E; Endo, M; Hatano, M; Imamura, T; Inaba, T; Kinugawa, K; Komuro, I; Maki, H; Nitta, D | 1 |
| Fujino, Y; Ohta, N; Shibata, SC; Uchiyama, A | 1 |
| Bai, Y; Chen, Q; Feng, C; Ji, T; Qin, Y; Sun, L; Ye, X; Zhao, X; Zhu, J | 1 |
| Arashi, T; Haruyama, N; Mae, T; Takata, J | 1 |
| Doi, K; Hiruma, T; Inokuchi, R; Nakajima, S; Nakamura, K; Tokunaga, K | 1 |
| Aoyama, H; Aoyama, Y; Otsuka, Y | 1 |
| Horigome, H; Iwamoto, M; Miura, M; Miyazaki, A; Nagano, T; Ohashi, N; Ono, H; Sagawa, K; Sakaguchi, H; Sumitomo, N; Suzuki, T; Takahashi, K; Takamuro, M; Takigiku, K; Tokunaga, C; Ueda, H; Ushinohama, H; Yoshimoto, J | 1 |
| Iwasaki, T; Naruo, H; Tsuneyoshi, I; Yano, T | 1 |
| Ishimura, N; Kumano, H; Morioka, M; Nishiwada, M; Okita, T; Shinjo, T; Uji, M | 1 |
| Fujiwara, H; Kawamura, T; Namai, A; Sakurai, M | 1 |
| Fukutomi, T; Nishimori, H; Radhakrishnan, G; Sasaguri, S; Wariishi, S; Yamamoto, M; Yamashita, K | 1 |
| Kawamura, T; Namai, A; Sakurai, M; Yoshioka, I | 1 |
| Goto, K; Noguchi, T; Ohchi, Y; Shingu, C; Yamamoto, S; Yasuda, N | 1 |
| Tanaka, K | 1 |
| Abe, T; Fukuda, T; Haruna, T; Inoko, M; Ito, H; Miyamoto, S; Nakane, E; Nohara, R; Sasaki, K; Uehara, K; Ueyama, K | 1 |
| Kurosawa, H; Sato, Y; Seto, Y; Takase, S; Wakamatsu, H; Yokoyama, H | 1 |
| Hata, M; Hirayama, A; Minami, K; Nakai, T; Sezai, A; Shiono, M; Wakui, S; Yoshitake, I | 1 |
| Ibe, T; Kamiyoshihara, M; Kawashima, O; Nagashima, T; Nakano, T; Shimizu, K; Takeyoshi, I | 1 |
| Funakoshi, Y; Maeda, H; Maekura, R; Nojiri, T; Okumura, M; Takeuchi, Y; Yamamoto, K | 1 |
| Bessho, R; Fujii, M; Ochi, M; Shimizu, K; Takeda, S; Terajima, K | 1 |
| Hosoda, S; Kasanuki, H; Kitakaze, M; Namiki, A; Sakamoto, A; Takamoto, S | 1 |
| Akaishi, M | 1 |
| Fukushima, S; Kuratani, T; Miyagawa, S; Nishi, H; Saito, S; Sakaguchi, T; Sawa, Y; Ueno, T; Yoshikawa, Y | 1 |
| Hata, M; Hirayama, A; Kunimoto, S; Nakai, T; Sezai, A; Shiono, M; Yoshitake, I | 1 |
| Hayashida, Y; Ito, N; Kuwahara, G; Minematsu, N; Morishige, N; Nishimi, M; Sukehiro, Y; Tashiro, T; Teratani, H | 1 |
| Hirai, H; Hosono, M; Nakahira, A; Sakaguchi, M; Sasaki, Y; Seo, H; Suehiro, S | 1 |
| Kim, C; Kohda, S; Nakanishi, K; Sakamoto, A; Takeda, S | 1 |
| Endo, I; Inoue, N; Konishi, R; Maeda, R; Seo, N | 1 |
| Furuhashi, K; Maruyama, K; Suzuki, Y | 1 |
| Igarashi, K; Imai, M; Kanai, M; Miura, K; Okazaki, A; Sakai, H | 1 |
| Goto, M; Isomine, S; Kanazawa, T; Mayahara, T; Nakajima, H; Sakaida, K; Sato, M | 1 |
| Hongo, T; Ogawa, R; Sakamoto, A; Yoshida, Y | 1 |
| Kitoh, T; Kobayashi, K; Otagiri, T; Satoh, N | 1 |
| Akada, S; Hongo, T; Miyagi, Y; Sakamoto, A; Sato, C; Takeda, S; Tanaka, K; Terajima, K; Yoshida, Y | 1 |
| Atarashi, H; Endoh, Y; Hayakawa, H; Ino, T; Kuruma, A; Saitoh, H; Yashima, M | 1 |
10 review(s) available for landiolol and Atrial Fibrillation
| Article | Year |
|---|---|
Landiolol for the prevention of postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis.
Topics: Atrial Fibrillation; Cardiac Surgical Procedures; Humans; Morpholines; Postoperative Complications; Randomized Controlled Trials as Topic | 2023 |
[The Role of Ultrarapid Acting Betablocker Esmolol and Landiolol in Critically Ill Patients].
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Critical Illness; Humans; Morpholines; Propanolamines; Urea | 2019 |
Cost-Effectiveness Analysis of Landiolol, an Ultrashort-Acting Beta-Blocker, for Prevention of Postoperative Atrial Fibrillation for the Germany Health Care System.
Topics: Atrial Fibrillation; Cost-Benefit Analysis; Delivery of Health Care; Germany; Humans; Morpholines; Postoperative Complications; Urea | 2020 |
Novel rate control strategy with landiolol in patients with cardiac dysfunction and atrial fibrillation.
Topics: Atrial Fibrillation; Humans; Japan; Morpholines; Urea | 2020 |
Beta-Blocker Landiolol Hydrochloride in Preventing Atrial Fibrillation Following Cardiothoracic Surgery: A Systematic Review and Meta-Analysis.
Topics: Atrial Fibrillation; Humans; Morpholines; Postoperative Complications; Treatment Outcome; Urea | 2022 |
Prevention of atrial fibrillation after cardiac surgery using low-dose landiolol: A systematic review and meta-analysis.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Dose-Response Relationship, Drug; Hospital Mortality; Humans; Incidence; Morpholines; Odds Ratio; Perioperative Care; Postoperative Complications; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Treatment Outcome; Urea | 2017 |
Landiolol: A Review in Tachyarrhythmias.
Topics: Administration, Intravenous; Adrenergic beta-1 Receptor Antagonists; Atrial Fibrillation; Dose-Response Relationship, Drug; Drug Approval; Heart Failure; Heart Rate; Humans; Japan; Morpholines; Tachycardia; Tachycardia, Supraventricular; Treatment Outcome; Urea; Ventricular Dysfunction, Left | 2018 |
Landiolol hydrochloride for prevention of atrial fibrillation after cardiac surgery: a meta-analysis.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; Incidence; Morpholines; Postoperative Complications; Premedication; Risk Factors; Survival Rate; Treatment Outcome; Urea | 2014 |
Perioperative landiolol administration reduces atrial fibrillation after cardiac surgery: A meta-analysis of randomized controlled trials.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; Incidence; Japan; Morpholines; Postoperative Complications; Randomized Controlled Trials as Topic; Treatment Outcome; Urea | 2014 |
Are beta-blockers effective for preventing post-coronary artery bypass grafting atrial fibrillation? Direct and network meta-analyses.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Bayes Theorem; Bisoprolol; Coronary Artery Bypass; Humans; Incidence; Morpholines; Network Meta-Analysis; Randomized Controlled Trials as Topic; Urea | 2016 |
20 trial(s) available for landiolol and Atrial Fibrillation
| Article | Year |
|---|---|
Effects of Landiolol on Macrocirculatory Parameters and Left and Right Ventricular Performances Following Cardiac Surgery: A Randomized Controlled Trial.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; Morpholines; Postoperative Complications; Prospective Studies; Urea | 2022 |
Comparison of landiolol and amiodarone for the treatment of new-onset atrial fibrillation after cardiac surgery (FAAC) trial: study protocol for a randomized controlled trial.
Topics: Amiodarone; Atrial Fibrillation; Cardiac Surgical Procedures; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Retrospective Studies; Single-Blind Method | 2023 |
Open-Label Two-Dose Pilot Study of Landiolol for the Treatment of Atrial Fibrillation/Atrial Flutter in Caucasian Patients.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Flutter; Humans; Middle Aged; Morpholines; Pilot Projects; Prospective Studies; Urea | 2019 |
Preventive effect of low-dose landiolol on postoperative atrial fibrillation study (PELTA study).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Surgical Procedures; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Morpholines; Postoperative Complications; Prospective Studies; Treatment Outcome; Urea | 2020 |
Microcirculatory effects of landiolol: a double-blind, randomised, controlled study after cardiac surgery.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Double-Blind Method; Heart Rate; Humans; Microcirculation; Morpholines; Prospective Studies; Time Factors; Treatment Outcome; Urea | 2021 |
The suppressive effects of landiolol administration on the occurrence of postoperative atrial fibrillation and tachycardia, and plasma IL-6 elevation in patients undergoing esophageal surgery: A randomized controlled clinical trial.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cytokines; Esophageal Neoplasms; Esophagectomy; Female; Humans; Incidence; Infusions, Intravenous; Interleukin-6; Length of Stay; Male; Middle Aged; Morpholines; Perioperative Care; Postoperative Complications; Prospective Studies; Tachycardia, Sinus; Urea | 2017 |
Randomized clinical trial of landiolol hydrochloride for the prevention of atrial fibrillation and postoperative complications after oesophagectomy for cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Carcinoma, Squamous Cell; Double-Blind Method; Esophageal Neoplasms; Esophagectomy; Female; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Treatment Outcome; Urea | 2017 |
Prevention of atrial fibrillation with ultra-low dose landiolol after off-pump coronary artery bypass grafting.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distribution; Coronary Artery Bypass, Off-Pump; Diltiazem; Female; Hemodynamics; Humans; Incidence; Japan; Male; Middle Aged; Morpholines; Multivariate Analysis; Odds Ratio; Prospective Studies; Risk Factors; Single-Blind Method; Time Factors; Treatment Outcome; Urea | 2014 |
Perioperative use of a beta blocker in coronary artery bypass grafting.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Atrial Fibrillation; Biomarkers; C-Reactive Protein; Coronary Artery Bypass; Creatine Kinase, MB Form; Disease-Free Survival; Drug Administration Schedule; Humans; Incidence; Inflammation; Infusions, Parenteral; Japan; Male; Middle Aged; Morpholines; Prospective Studies; Time Factors; Treatment Outcome; Troponin I; Urea | 2013 |
Impacts of patient characteristics on the effectiveness of landiolol in AF/AFL patients complicated with LV dysfunction: Subgroup analysis of the J-Land study.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Digoxin; Drug Monitoring; Female; Heart Rate; Humans; Male; Middle Aged; Morpholines; Severity of Illness Index; Stroke Volume; Treatment Outcome; Urea; Ventricular Dysfunction, Left | 2014 |
Safety and efficacy of landiolol hydrochloride for prevention of atrial fibrillation after cardiac surgery in patients with left ventricular dysfunction: Prevention of Atrial Fibrillation After Cardiac Surgery With Landiolol Hydrochloride for Left Ventric
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Female; Humans; Male; Morpholines; Postoperative Complications; Prospective Studies; Urea; Ventricular Dysfunction, Left | 2015 |
Landiolol infusion during general anesthesia does not prevent postoperative atrial fibrillation in patients undergoing lung resection.
Topics: Adrenergic beta-Antagonists; Aged; Anesthesia, General; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Incidence; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Pneumonectomy; Postoperative Complications; Survival Rate; Urea | 2016 |
Study design for control of HEART rate in inFant and child tachyarrhythmia with heart failure Using Landiolol (HEARTFUL): A prospective, multicenter, uncontrolled clinical trial.
Topics: Adolescent; Adrenergic beta-Antagonists; Atrial Fibrillation; Atrial Flutter; Child; Child, Preschool; Female; Heart Failure; Heart Rate; Humans; Infant; Infusions, Intravenous; Male; Morpholines; Research Design; Tachycardia; Urea | 2017 |
Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: new evidence from the PASCAL trial.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; Female; Heart Rate; Hospital Costs; Humans; Japan; Logistic Models; Male; Middle Aged; Morpholines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Urea | 2011 |
Effect of postoperative landiolol administration for atrial fibrillation after off pump coronary artery bypass surgery.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Coronary Artery Bypass, Off-Pump; Coronary Artery Disease; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Heart Rate; Humans; Injections, Intravenous; Male; Morpholines; Postoperative Care; Postoperative Complications; Prospective Studies; Treatment Outcome; Urea | 2012 |
Landiolol, an ultra-short-acting β₁-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Cardiac Surgical Procedures; Cardiovascular Agents; Diltiazem; Female; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Prospective Studies; Urea | 2012 |
Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Antioxidants; Arginine; Atrial Fibrillation; Biomarkers; Bisoprolol; C-Reactive Protein; Coronary Artery Bypass; Creatine Kinase, MB Form; Drug Administration Schedule; Fatty Acid Binding Protein 3; Fatty Acid-Binding Proteins; Female; Hemodynamics; Humans; Infusions, Intravenous; Japan; Male; Middle Aged; Morpholines; Natriuretic Peptide, Brain; Pilot Projects; Serum Amyloid P-Component; Single-Blind Method; Time Factors; Treatment Outcome; Troponin I; Urea | 2012 |
Safety and efficacy of an ultrashort-acting β1-blocker on left ventricular dysfunction.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Morpholines; Premedication; Urea; Ventricular Dysfunction, Left | 2012 |
Efficacy of landiolol hydrochloride for prevention of atrial fibrillation after heart valve surgery.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Rate; Heart Valve Prosthesis Implantation; Humans; Infusions, Intravenous; Male; Morpholines; Postoperative Complications; Prospective Studies; Treatment Outcome; Urea | 2012 |
Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Morpholines; Tachycardia, Supraventricular; Tachycardia, Ventricular; Urea; Ventricular Premature Complexes | 2000 |
51 other study(ies) available for landiolol and Atrial Fibrillation
| Article | Year |
|---|---|
Clinical usefulness of left ventricular outflow tract velocity time integral for heart failure with reduced ejection fraction with rapid atrial fibrillation during landiolol treatment.
Topics: Atrial Fibrillation; Heart Failure; Hospital Mortality; Humans; Morpholines; Prognosis; Prospective Studies; Stroke Volume; Urea; Ventricular Function, Left | 2022 |
The application of landiolol in the cardiovascular and intensive care
Topics: Atrial Fibrillation; Critical Care; Heart Rate; Humans; Morpholines; Myocardial Infarction; Urea | 2022 |
Control of Heart Rate in Infant and Child Tachyarrhythmia With Reduced Cardiac Function Using Landiolol (HEARTFUL) - Results of a Prospective, Multicenter, Uncontrolled Clinical Study.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Child; Heart Rate; Humans; Hypotension; Infant; Prospective Studies; Tachycardia; Urea | 2022 |
Prognostic Impact of Landiolol in Patients with Acute Heart Failure and Atrial Fibrillation with Rapid Ventricular Rates: A Pilot Observational Study.
Topics: Atrial Fibrillation; Heart Failure; Humans; Morpholines; Prognosis | 2022 |
[Effect of Landiolol for Atrial Fibrillation after Open Heart Surgery].
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Cardiac Surgical Procedures; Female; Humans; Male; Morpholines; Postoperative Complications; Risk Factors; Urea | 2023 |
A Penny Saved Should Be a Penny Earned.
Topics: Atrial Fibrillation; Cost-Benefit Analysis; Germany; Humans; Morpholines; Urea | 2020 |
Comparison of Landiolol and Digoxin as an Intravenous Drug for Controlling the Heart Rate in Patients with Atrial Fibrillation and Severely Depressed Left Ventricular Function.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; Digoxin; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Morpholines; Retrospective Studies; Severity of Illness Index; Stroke Volume; Tachycardia; Treatment Outcome; Urea; Ventricular Dysfunction, Left | 2020 |
Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients.
Topics: Aged; Atrial Fibrillation; COVID-19 Drug Treatment; Critical Illness; Female; Heart Rate; Hospitalization; Humans; Intensive Care Units; Male; Morpholines; Patient Safety; Prospective Studies; Treatment Outcome; Urea | 2021 |
Suppression of amiodarone-induced torsade de pointes by landiolol in a patient with atrial fibrillation-mediated cardiomyopathy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathies; Electrocardiography; Female; Humans; Morpholines; Torsades de Pointes; Urea | 2021 |
Safety and Efficacy of Landiolol Hydrochloride in Children with Tachyarrhythmia of Various Etiologies.
Topics: Atrial Fibrillation; Child; Humans; Infant; Morpholines; Retrospective Studies; Tachycardia; Urea | 2021 |
Switching Therapy from Intravenous Landiolol to Transdermal Bisoprolol in a Patient with Thyroid Storm Complicated by Decompensated Heart Failure and Gastrointestinal Dysfunction.
Topics: Administration, Cutaneous; Administration, Intravenous; Adrenergic beta-Antagonists; Adult; Atrial Fibrillation; Bisoprolol; Female; Gastrointestinal Diseases; Heart Failure; Humans; Morpholines; Thyroid Crisis; Treatment Outcome; Urea | 2017 |
[Postoperative Atrial Fibrillation in Patients who Underwent Thoracic Aortic Surgery].
Topics: Aged; Aged, 80 and over; Aorta, Thoracic; Atrial Fibrillation; Female; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Risk Factors; Thoracic Surgical Procedures; Urea | 2018 |
Landiolol hydrochloride for preventing postoperative atrial fibrillation.
Topics: Atrial Fibrillation; Humans; Incidence; Morpholines; Risk Factors; Urea | 2018 |
Differential Effectiveness of Landiolol Between Atrial Fibrillation and Atrial Flutter/Atrial Tachycardia Patients With Left Ventricular Dysfunction.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Humans; Male; Middle Aged; Morpholines; Retrospective Studies; Tachycardia; Urea; Ventricular Dysfunction, Left | 2019 |
What Determines the Response to Landiolol?
Topics: Atrial Fibrillation; Atrial Flutter; Humans; Morpholines; Tachycardia; Urea; Ventricular Dysfunction, Left | 2019 |
What Determines the Response to Landiolol? - Reply.
Topics: Atrial Fibrillation; Atrial Flutter; Humans; Morpholines; Tachycardia; Urea; Ventricular Dysfunction, Left | 2019 |
A prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Atrial Flutter; Chronic Disease; Female; Heart Failure; Heart Rate; Humans; Japan; Male; Middle Aged; Morpholines; Prospective Studies; Surveys and Questionnaires; Treatment Outcome; Urea | 2019 |
Atrial fibrillation after esophageal cancer surgery: an analysis of 207 consecutive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Colon; Esophageal Neoplasms; Esophagectomy; Esophagoplasty; Female; Heart Rate; Humans; Ileum; Logistic Models; Male; Middle Aged; Morpholines; Postoperative Complications; Risk Factors; Tachycardia; Urea | 2014 |
Novel use of the ultra-short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Atrial Fibrillation; Blood Pressure; Drug Administration Schedule; Female; Heart Failure; Heart Rate; Humans; Infusions, Intravenous; Japan; Male; Middle Aged; Morpholines; Tachycardia, Supraventricular; Time Factors; Treatment Outcome; Urea | 2014 |
A low-dose β1-blocker effectively and safely slows the heart rate in patients with acute decompensated heart failure and rapid atrial fibrillation.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Female; Heart Failure; Heart Rate; Humans; Male; Morpholines; Urea | 2014 |
Effect of landiolol hydrochloride after off-pump coronary artery bypass.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass, Off-Pump; Drug Administration Schedule; Female; Heart Rate; Humans; Incidence; Infusions, Intravenous; Intensive Care Units; Japan; Length of Stay; Male; Middle Aged; Morpholines; Time Factors; Treatment Outcome; Urea | 2013 |
The role of β-blockers in cardiac perioperative management.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Drug Administration Schedule; Humans; Infusions, Intravenous; Injections, Intravenous; Morpholines; Risk Factors; Treatment Outcome; Urea | 2014 |
Preventive effect of intraoperative landiolol administration on atrial fibrillation after off-pump coronary artery bypass grafting.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Coronary Artery Bypass, Off-Pump; Drug Monitoring; Female; Heart Rate; Humans; Incidence; Intraoperative Care; Japan; Male; Morpholines; Postoperative Complications; Retrospective Studies; Time Factors; Treatment Outcome; Urea | 2014 |
Effect of landiolol hydrochloride on tachyarrhythmia after esophagectomy.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel Blockers; Digitalis Glycosides; Drug Therapy, Combination; Esophagectomy; Female; Heart Rate; Humans; Japan; Male; Middle Aged; Morpholines; Retrospective Studies; Tachycardia; Treatment Outcome; Urea | 2014 |
Design of a prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey.
Topics: Adrenergic beta-Antagonists; Adverse Drug Reaction Reporting Systems; Aged; Atrial Fibrillation; Atrial Flutter; Female; Heart Failure; Humans; Japan; Male; Morpholines; Prospective Studies; Research Design; Urea | 2015 |
Thyroid Storm with Heart Failure Treated with a Short-acting Beta-adrenoreceptor Blocker, Landiolol Hydrochloride.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Electric Countershock; Female; Heart Failure; Heart Rate; Humans; Infusions, Intravenous; Morpholines; Tachycardia; Thyroid Crisis; Thyroidectomy; Treatment Outcome; Urea | 2015 |
An Experience of Landiolol Use for an Advanced Heart Failure Patient With Severe Hypotension.
Topics: Adrenergic beta-1 Receptor Antagonists; Atrial Fibrillation; Biological Availability; Cardiomyopathy, Dilated; Electrocardiography; Heart Failure; Humans; Hypotension; Intra-Aortic Balloon Pumping; Male; Mitral Valve Insufficiency; Morpholines; Severity of Illness Index; Treatment Outcome; Urea; Ventricular Dysfunction, Left; Young Adult | 2015 |
Efficacy and Safety of Landiolol Compared to Amiodarone for the Management of Postoperative Atrial Fibrillation in Intensive Care Patients.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Critical Care; Female; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Retrospective Studies; Urea | 2016 |
Alteration of fatal 1:1 conducted atrial flutter to less conducted ratio by landiolol infusion.
Topics: Aged, 80 and over; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Humans; Male; Morpholines; Urea; Ventricular Dysfunction, Left | 2016 |
Switching therapy from intravenous beta blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Blood Pressure; Critical Care; Female; Heart Rate; Humans; Injections, Intravenous; Male; Middle Aged; Morpholines; Retrospective Studies; Transdermal Patch; Urea | 2016 |
Use of landiolol for treatment of atrial fibrillation in a patient with terminal cancer.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Colonic Neoplasms; Female; Humans; Morpholines; Tachycardia; Terminal Care; Urea | 2010 |
[Use of landiolol hydrochloride for the prevention of atrial fibrillation after lung resection].
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Male; Middle Aged; Morpholines; Pneumonectomy; Postoperative Complications; Urea | 2008 |
Effect of low-dose landiolol, an ultrashort-acting beta-blocker, on postoperative atrial fibrillation after CABG surgery.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiopulmonary Bypass; Coronary Artery Bypass; Drug Administration Schedule; Female; Half-Life; Humans; Male; Middle Aged; Morpholines; Retrospective Studies; Treatment Outcome; Urea | 2009 |
Postoperative administration of landiolol hydrochloride for patients with supraventricular arrhythmia: the efficacy of sustained intravenous infusion at a low dose.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Atrial Premature Complexes; Blood Pressure; Drug Administration Schedule; Female; Heart Rate; Humans; Infusions, Intravenous; Male; Middle Aged; Morpholines; Postoperative Care; Surgical Procedures, Operative; Tachycardia, Sinus; Time Factors; Treatment Outcome; Urea | 2009 |
Postoperative treatment of carvedilol following low dose landiolol has preventive effect for atrial fibrillation after coronary artery bypass grafting.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Carbazoles; Carvedilol; Coronary Artery Bypass; Female; Humans; Male; Middle Aged; Morpholines; Propanolamines; Retrospective Studies; Tachycardia; Treatment Outcome; Urea | 2009 |
Conversion of atrial flutter to sinus rhythm during landiolol infusion.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Hernia, Inguinal; Humans; Infusions, Intravenous; Intraoperative Complications; Laparoscopy; Morpholines; Treatment Outcome; Urea | 2010 |
[Effects of landiolol on hemodynamic improvement and prevention of atrial fibrillation in the perioperative period of off-pump coronary artery bypass grafting].
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Coronary Artery Bypass, Off-Pump; Female; Hemodynamics; Humans; Male; Morpholines; Perioperative Care; Urea | 2010 |
[Clinical analysis of precaution against atrial fibrillation following cardiac surgery: landiolol or amiodarone?].
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Female; Humans; Male; Morpholines; Postoperative Complications; Urea | 2010 |
[Effect of intra-operative low-dose infusion of landiolol hydrochloride on post-operative atrial fibrillation after off-pump coronary artery bypass grafting].
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Coronary Artery Bypass, Off-Pump; Female; Humans; Infusions, Intravenous; Intraoperative Period; Male; Morpholines; Postoperative Complications; Retrospective Studies; Urea | 2010 |
Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Flutter; Female; Heart Rate; Humans; Infusions, Intravenous; Lung Diseases; Male; Middle Aged; Morpholines; Retrospective Studies; Secondary Prevention; Tachycardia, Supraventricular; Treatment Outcome; Urea | 2012 |
Efficacy of low-dose landiolol, an ultrashort-acting β-blocker, on postoperative atrial fibrillation in patients undergoing pulmonary resection for lung cancer.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Female; Hemodynamics; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Morpholines; Pneumonectomy; Postoperative Complications; Urea | 2011 |
Intravenous infusion of ultra-short-acting β-blocker for postoperative atrial fibrillation is the one of choice.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Cardiac Surgical Procedures; Cardiovascular Agents; Diltiazem; Female; Humans; Male; Morpholines; Postoperative Complications; Urea | 2012 |
Efficacy of landiolol hydrochloride for atrial fibrillation after open heart surgery.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; Cardiac Surgical Procedures; Female; Heart Rate; Humans; Male; Middle Aged; Morpholines; Retrospective Studies; Treatment Outcome; Urea | 2013 |
Postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting or cardiac valve surgery: intraoperative use of landiolol.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Heart Valve Prosthesis Implantation; Humans; Intraoperative Care; Middle Aged; Morpholines; Postoperative Complications; Retrospective Studies; Urea | 2013 |
[Successful control of rapid heart rate in a patient with atrial fibrillation by continuous intravenous administration of landiolol hydrochloride].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Infusions, Intravenous; Male; Morpholines; Tachycardia; Urea | 2003 |
[Clinical experience of landiolol for the treatment of intraoperative rapid atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Cardiopulmonary Bypass; Cardiovascular Surgical Procedures; Female; Humans; Intraoperative Complications; Morpholines; Reoperation; Treatment Outcome; Urea | 2004 |
[Perioperative heart rate control with landiolol for a patient with rapid atrial fibrillation complicated with low cardiac function].
Topics: Anesthesia, Epidural; Anesthesia, General; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Heart; Heart Rate; Humans; Lung Neoplasms; Male; Middle Aged; Morpholines; Pancreatic Neoplasms; Urea | 2004 |
Conversion of atrial fibrillation to sinus rhythm during landiolol infusion.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Infusions, Intravenous; Intracranial Aneurysm; Intraoperative Care; Morpholines; Urea | 2004 |
Successful management of tachycardiac atrial fibrillation in a septic patient with landiolol.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Hemodynamics; Humans; Intraoperative Complications; Laparoscopy; Male; Morpholines; Peritonitis; Sepsis; Tachycardia; Urea | 2005 |
[Effect of landiolol on heart rate control of atrial fibrillation in a patient with sick sinus syndrome under ventricular pacing].
Topics: Anesthesia, General; Anti-Asthmatic Agents; Arthroplasty, Replacement; Atrial Fibrillation; Cardiac Pacing, Artificial; Heart Rate; Heart Ventricles; Humans; Infusions, Intravenous; Intraoperative Care; Intraoperative Complications; Male; Middle Aged; Morpholines; Shoulder Joint; Sick Sinus Syndrome; Treatment Outcome; Urea | 2006 |
Clinical role and efficacy of landiolol in the intensive care unit.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Blood Pressure; Catecholamines; Female; Heart Rate; Humans; Intensive Care Units; Male; Middle Aged; Morpholines; Myocardial Ischemia; Retrospective Studies; Time Factors; Treatment Outcome; Urea | 2008 |